POST Online Media Lite Edition


Spark Therapeutics appoints Federico Mingozzi as CSO

Staff Writer |
Philadelphia, Pa., USA - September 26, 2017, Philadelphia, Pa., USA - Spark Therapeutics, a fully integrated gene therapy company, announced the appointment of Federico Mingozzi as chief scientific officer.

Article continues below

Dr. Mingozzi joins Spark Therapeutics from the French National Institute of Health and Medical Research (INSERM) and Genethon, a leading French nonprofit R&D organization.

He serves as faculty at the Pierre and Marie Curie University in Paris and Universitat Autonoma de Barcelona, Spain.

Dr. Mingozzi has had a distinguished career in gene therapy research, including earlier as director of translational research, Center for Cellular and Molecular Therapeutics, at Children’s Hospital of Philadelphia, where he was involved in the development of gene therapies based on the AAV vector platform.

Throughout his career, Dr. Mingozzi has contributed to more than 90 publications, including seminal findings in the field of AAV gene therapy.

LATEST 5 MOVES FROM Pennsylvania 

What to read next

Spark New Zealand announces new CEO for Spark Ventures
Director Michael Whitaker steps down from Spark Ventures
Spark Networks names Shailen Mistry as chief technology officer